Product Description
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Ireland
Approved Indications: None
Known Adverse Events: None
Company: National Heart, Lung, and Blood Institute (NHLBI)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Coronary Artery Disease|Cardiac Arrest|Myocardial Ischemia|Myocardial Infarction|Death, Sudden, Cardiac
Phase 2: Death, Sudden, Cardiac|Cardiac Arrhythmias|Myocardial Infarction|Ventricular Fibrillation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00000504 |
NCT00000504 | P2 |
Completed |
Death, Sudden, Cardiac|Cardiac Arrhythmias|Myocardial Infarction|Ventricular Fibrillation |
None |
2019-03-21 |
Treatments |
|
NCT00000526 |
CAST | P3 |
Completed |
Coronary Artery Disease|Myocardial Infarction|Cardiac Arrest|Myocardial Ischemia|Death, Sudden, Cardiac |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/01/2023 |
PubMed |
Encainide, a class Ic anti-arrhythmic agent, blocks voltage-dependent potassium channels in coronary artery smooth muscle cells. |
|
01/01/2023 |
PubMed |
Flecainide in clinical practice. |